<DOC>
	<DOCNO>NCT00626405</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , paclitaxel albumin-stabilized nanoparticle formulation , carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . It yet know whether bevacizumab effective give together temozolomide paclitaxel albumin-stabilized nanoparticle formulation carboplatin kill malignant melanoma cell . PURPOSE : This randomized phase II trial study side effect give temozolomide together bevacizumab see well work compare give bevacizumab together paclitaxel albumin-stabilized nanoparticle formulation carboplatin treat patient stage IV malignant melanoma remove surgery .</brief_summary>
	<brief_title>Bevacizumab Temozolomide Bevacizumab Paclitaxel Albumin-Stabilized Nanoparticle Formulation Carboplatin Treating Patients With Stage IV Malignant Melanoma That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess anti-tumor activity , term percentage patient treat regimens progression-free 6 month . - To assess safety profile treatment regimen . Secondary - To estimate response rate patient treat regimen . - To estimate distribution progression-free survival time overall survival time patient treat regimen . Tertiary - To examine impact therapy angiogenesis immune homeostasis . OUTLINE : Patients stratify accord ECOG performance status ( 0 vs 1 ) location metastatic disease ( M1a [ skin subcutaneous tissue lymph node ] v M1b [ lung ] v M1c [ visceral site ] ) randomize 1 2 treatment arm . - Arm I : Patients receive oral temozolomide day 1-5 bevacizumab IV 30-90 minute day 1 15 . ( close accrual 8/21/09 ) - Arm II : Patients receive bevacizumab IV 30-90 minute day 1 15 , paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute day 1 , 8 , 15 , carboplatin IV 30 minute day 1 . In arm , treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo blood sample collection periodically VEGF plasma level analysis change immune homeostasis . Beginning study entry , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologic confirm diagnosis malignant melanoma Stage IV disease Not amenable tosurgery Measurable disease least one lesion whose long diameter canbe measure ≥ 20 mm CT MRI scan OR ≥ 10 mm spiral CT No disease measurable physical examination No brain metastasis per MRI CT No radiographically document invasion adjacent organ ( duodenum , stomach , etc . ) tumor invade major blood vessel ECOG performance status 01 Life expectancy ≥ 4 month ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL ( transfusion allow ) Creatinine ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL ( unless Gilbert syndrome ) AST ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Urine protein : creatinine ratio &lt; 1.0 screen ORproteinuria &lt; 2+ urine dipstick protein ≤ 1 g 24hour urine collection Negative serum pregnancy test Not pregnant nursing Fertile patient must use effective contraception Active infection require parenteral antibiotic Poorly control high blood pressure ( ≥ 150 mm Hg systolic and/or100 mm Hg diastolic ) despite treatment NYHA class IIIV congestive heart failure Serious cardiac arrhythmia require medication Myocardial infarction unstable angina within past 6 month Clinically significant peripheral vascular disease Deep venous thrombosis pulmonary embolus within past year Active bleeding pathological condition carry high risk bleeding ( e.g. , know esophageal varix ) Serious , nonhealing wound ( include wound heal secondary intention ) , ulcer bone fracture Abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month History CNS disease ( e.g. , primary brain tumor , vascular abnormality , etc . ) Clinically significant stroke TIA within past 6 month Seizures control standardmedical therapy Peripheral neuropathy ≥ grade 2 History malignancy within past 5 year except basal cell squamous cell carcinoma skin treatable local resection carcinoma situ cervix Significant traumatic injury within past 4 week History hypertensive crisis hypertensive encephalopathy Active recent ( ≤ 30 day ) history hemoptysis ( ≥ ½ teaspoon bright red blood per episode ) Known hypersensitivity component bevacizumab Known HIV positive Current known history hepatitis Prior adjuvant chemotherapy and/or immunotherapy cancer allow No prior treatment agent disrupt VEGF activity ( i.e. , bevacizumab , VEGFtrap , antiVEGFR Mab ) No ongoing need fulldose oral parenteral anticoagulation No ongoing antiplatelet treatment lowdose aspirin ( i.e. , aspirin 81 mg daily ) No investigational agent within past 4 week No major surgical procedure open biopsy within past 4 week No fine needle aspiration core biopsy within past 7 day No prior chemotherapy metastatic setting No prior treatment sunitinib malate sorafenib No prior treatment taxanebased chemotherapy Patients &gt; 25 % functional bone marrow irradiate eligible trial No adjuvant radiation therapy within past 4 week More 2 week since prior concurrent palliative radiation therapy No concurrent major surgical procedure No concurrent participation another clinical study procedure agent treat primary study malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>stage IV melanoma</keyword>
</DOC>